Does brepocitinib benefit patients with psoriatic arthritis?

Brepocitinib is an oral drug that inhibits certain enzymes involved in inflammation—called tyrosine kinase 2 and Janus kinase 1—and is being tested for the treatment of several immunological diseases. A phase IIb randomized clinical trial published in Arthritis & Rheumatology recently generated promising efficacy and safety data for the use of brepocitinib in adults with moderately-to-severely active psoriatic arthritis.

source https://medicalxpress.com/news/2023-05-brepocitinib-benefit-patients-psoriatic-arthritis.html